Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Inhibitor Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Inhibitor Therapeutics, Inc.

INTI

Inhibitor Therapeutics, Inc.

About Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on repurposing approved drugs, particularly itraconazole, for cancer treatment. It targets cancers such as basal cell carcinoma, prostate, and lung cancers by developing Hedgehog pathway inhibitors. The company advances clinical research, secures intellectual property, and seeks FDA designations to expedite approvals, aiming for market exclusivity and strategic partnerships in oncology therapeutics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Inhibitor Therapeutics, Inc.

1
1
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics Reports Q1 2026 Financial Results with Increased Net Loss

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics Reports $3.3 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics Reports Q3 2025 Financial Results, Focuses on Drug Development

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics Reports Q2 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics Reports Q1 2025 Financial Results with Net Loss of $632,846

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics Reports Financial Performance and Strategic Developments for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics Reports Financial Results, Focuses on Cancer Treatment Development

Via official filing (AI summary) | over 1 year ago | 0 comments